Clinical Trial Update: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI [Phase 2]

View source ↗

Summary

Phase 2 safety, PK, and PD study of repeat doses of inhaled nemiralisib in patients with Activated PI3K-delta Syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Activated Pi3k-delta Syndrome

Drugs mentioned

• Nemiralisib (nemiralisib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Activated PI3K-delta Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-06-18